Premium
Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials
Author(s) -
Langabeer S. E.,
Walker H.,
Rogers J. R.,
Burnett A. K.,
Wheatley K.,
Swirsky D.,
Goldstone A. H.,
Linch D. C.
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.4663270.x
Subject(s) - fusion transcript , incidence (geometry) , medicine , fusion gene , myeloid , oncology , gastroenterology , immunology , biology , gene , genetics , physics , optics
Acute myeloid leukaemia (AML) with the t(8;21)(q22;q22) is deemed to be a ‘good‐risk’ disease. 396 patients with AML at diagnosis were screened for the presence of t(8;21) and AML1/ETO fusion transcripts by cytogenetic and RT‐PCR techniques respectively. 32 cases of t(8;21) were detected, all of which were also PCR positive. A further 19 cases were detected at the molecular level, predominantly but not exclusively in M1 and M2 FAB types. Approximately 12% of all new cases of AML are estimated to have AML1/ETO fusion transcripts and it is suggested that molecular screening should be performed in all cases with the possible exception of the M3 FAB type.